Podium to Practice: EHA 2025 – Lymphoma: POLARGO

Podium to Practice: EHA 2025 – Lymphoma: POLARGO

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Carolyn Owen

Icon Chair Speaker

Speakers

Dr. Anca Prica

Dr. Mary Margaret Keating

Studies / Trials Discussed

S101 – POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA-R-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE RANDOMIZED PHASE III POLARGO TRIAL

Studies/trials discussed:

S101 – POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA-R-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE RANDOMIZED PHASE III POLARGO TRIAL
Tagged